Literature DB >> 1534515

Induction of interleukin-2 receptor by tumor necrosis factor alpha on cultured ovarian tumor-associated lymphocytes.

C G Ioannides1, B Fisk, B Tomasovic, R Pandita, B B Aggarwal, R S Freedman.   

Abstract

We have recently reported that autologous tumor-specific cytotoxic T lymphocyte (CTL) lines and clones can be developed from lymphocytes infiltrating ovarian malignant ascites (TAL). In this study, we investigated the biological effects of tumor necrosis factor alpha (TNF alpha) in the induction, expansion, long-term proliferation and lytic function of CD8+ TAL. TNF alpha up-regulated the IL-2 receptor (IL-2R) alpha chain (Tac antigen) on the surface of CD3+ CD8+ CD4- TAL, enhanced the proliferation of autologous tumor-specific CTL, and potentiated their lytic function in long-term cultures. Furthermore, in the induction and expansion phase of CD8+ TAL, the presence of TNF alpha was associated with a selective increase in CD8+ IL-2R+ (Tac+) cells, and subsequent decrease in CD4+ IL-2R+ (Tac+) cells. These results suggest that the observed facilitation of the outgrowth of CD8+ cells in TAL cultures may be due, at least in part, to the up-regulation of IL-2R, and indicate the usefulness of TNF alpha in the analysis of signalling in autologous tumor-reactive CTL.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534515     DOI: 10.1007/bf01741854

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  31 in total

1.  Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.

Authors:  Y L Wang; L S Si; A Kanbour; R B Herberman; T L Whiteside
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

2.  Inhibition of IL-2 receptor induction and IL-2 production in the human leukemic cell line Jurkat by a novel peptide inhibitor of protein kinase C.

Authors:  C G Ioannides; R S Freedman; R M Liskamp; N E Ward; C A O'Brian
Journal:  Cell Immunol       Date:  1990-11       Impact factor: 4.868

3.  In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.

Authors:  P J Spiess; J C Yang; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1987-11       Impact factor: 13.506

4.  Tumor necrosis factor alpha induces proteins that bind specifically to kappa B-like enhancer elements and regulate interleukin 2 receptor alpha-chain gene expression in primary human T lymphocytes.

Authors:  J W Lowenthal; D W Ballard; E Böhnlein; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

5.  Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation.

Authors:  J M Depper; W J Leonard; R J Robb; T A Waldmann; W C Greene
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

6.  Identification of a second T-cell antigen receptor in human and mouse by an anti-peptide gamma-chain-specific monoclonal antibody.

Authors:  C G Ioannides; K Itoh; F E Fox; R Pahwa; R A Good; C D Platsoucas
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

7.  Contrasting interleukin 2 binding properties of the alpha (p55) and beta (p70) protein subunits of the human high-affinity interleukin 2 receptor.

Authors:  J W Lowenthal; W C Greene
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

8.  High-affinity receptor-mediated internalization and degradation of interleukin 2 in human T cells.

Authors:  M Fujii; K Sugamura; K Sano; M Nakai; K Sugita; Y Hinuma
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

9.  The interleukin 2 receptor. Functional consequences of its bimolecular structure.

Authors:  H M Wang; K A Smith
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

10.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

2.  T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.

Authors:  J Shilyansky; M I Nishimura; J R Yannelli; Y Kawakami; L S Jacknin; P Charmley; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

3.  Functional role of IL-2 receptors on tumour-infiltrating lymphocytes.

Authors:  L Trentin; R Zambello; P Bulian; A Cerutti; A Milani; E Pirone; D Nitti; C Agostini; G Semenzato
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

4.  Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor.

Authors:  L Trentin; R Zambello; P Bulian; A Cerutti; C Enthammer; M Cassatella; D Nitti; M Lise; C Agostini; G Semenzato
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.